We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eidogen-Sertanty Licenses Kinase Database to Medisyn Technologies
News

Eidogen-Sertanty Licenses Kinase Database to Medisyn Technologies

Eidogen-Sertanty Licenses Kinase Database to Medisyn Technologies
News

Eidogen-Sertanty Licenses Kinase Database to Medisyn Technologies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eidogen-Sertanty Licenses Kinase Database to Medisyn Technologies "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eidogen-Sertanty, Inc. has announced that they have licensed their Kinase Knowledgebase™ to Medisyn Technologies.

This announcement comes after the significant expansion of the Eidogen Kinase Knowledgebase in July 2005, which now contains over 160,000 SAR data points and over 390,000 kinase compounds mined from scientific literature and patents.

The Kinase Knowledgebase is Eidogen-Sertanty's database of structure-activity relationships (SAR) and chemical synthesis data focused on protein kinases -- one of the therapeutically important classes of drug targets.

Medisyn entered into an annual license agreement of the Kinase Knowledgebase after an initial validation of the data quality.

"We were very pleased with the quality and comprehensiveness of Eidogen-Sertanty's kinase database," said David Land, President of Medisyn.

"Medisyn's value lies in our ability to make drug discovery faster, less expensive and more predictable for biotechnology and pharmaceutical companies.”

“The Kinase Knowledgebase broadens our palette of experimentally characterized compounds, saving preparation time and dollars in the application of our Fast Forward Engineering™ predictive discovery platform.”

“We're optimistic that the data quality will contribute further efficiencies to our drug discovery process."

"We are excited to add Medisyn to our growing customer base,” said Steve Muskal, CEO of Eidogen-Sertanty.

“The fact that early stage platform-based drug discovery companies like Medisyn find value in our kinase database content highlights the universal applicability of our content across small, medium, and large drug discovery organizations."

Advertisement